

Keith J. Miller, Esq.  
Michael J. Gesualdo, Esq.  
Bradley A. Suiters, Esq.  
**ROBINSON MILLER LLC**  
Ironside Newark  
110 Edison Place, Suite 302  
Newark, New Jersey 07102  
Tel: (973) 690-5400  
Fax: (973) 466-2761  
Email: [kmiller@rwmlegal.com](mailto:kmiller@rwmlegal.com)  
[mgesualdo@rwmlegal.com](mailto:mgesualdo@rwmlegal.com)  
[bsuiters@rwmlegal.com](mailto:bsuiters@rwmlegal.com)

*Attorneys for Plaintiffs*  
*Aragon Pharmaceuticals, Inc., Janssen*  
*Biotech, Inc., The Regents of the University of*  
*California, and Sloan-Kettering Institute for*  
*Cancer Research*

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

ARAGON PHARMACEUTICALS, INC.,  
JANSSEN BIOTECH, INC., THE  
REGENTS OF THE UNIVERSITY OF  
CALIFORNIA, and SLOAN-KETTERING  
INSTITUTE FOR CANCER RESEARCH,

Plaintiffs,

v.

HETERO LABS LIMITED UNIT V, and  
HETERO USA, INC.,

Defendants.

Civil Action No. \_\_\_\_\_

**COMPLAINT FOR PATENT  
INFRINGEMENT**

**(Filed Electronically)**

Plaintiffs Aragon Pharmaceuticals, Inc. (“Aragon”), Janssen Biotech, Inc. (“JBI”), The Regents of the University of California (“Regents”), and Sloan-Kettering Institute for Cancer Research (“Sloan-Kettering”) (collectively, “Plaintiffs”), for their Complaint against Defendants Hetero Labs Limited Unit V (“Hetero Labs”) and Hetero USA, Inc. (“Hetero USA”) (collectively, “Defendants”), hereby allege as follows:

### **NATURE OF THE ACTION**

1. This is a civil action for infringement of United States Patent Nos. 8,445,507 (“the 507 Patent”), 8,802,689 (“the 689 Patent”), 9,388,159 (“the 159 Patent”), 9,987,261 (“the 261 Patent”), 9,481,663 (“the 663 Patent”), 9,884,054 (“the 054 Patent”), RE49,353 (“the RE353 Patent”), 10,849,888 (“the 888 Patent”), 10,702,508 (“the 508 Patent”), and 11,963,952 (“the 952 Patent”) (collectively, the “Patents-In-Suit”).

2. This action relates to the submission of Abbreviated New Drug Application No. 220525 (“the ANDA”) by Defendants to the United States Food and Drug Administration (“FDA”) seeking approval to market a proposed generic version of Erleada<sup>®</sup> 240 mg tablets (“Proposed ANDA Product”) prior to the expiration of the Patents-In-Suit.

### **THE PARTIES**

3. Aragon is a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 10990 Wilshire Boulevard, Suite 440, Los Angeles, California 90024.

4. JBI is a corporation organized and existing under the laws of the Commonwealth of Pennsylvania, having its principal place of business at 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044.

5. Regents is a California non-profit constitutional corporation and the governing body of an educational institution, having its principal place of business at 1111 Franklin Street, Oakland, California 94607.

6. Sloan-Kettering is a corporation organized and existing under the laws of the State of New York, having its principal place of business at 1275 York Avenue, New York, New York 10065.

7. On information and belief, Hetero Labs is a corporation organized under the laws of India, having its principal place of business at Sy. No.: 439, 440, 441 & 458, TSIIC Formulation SEZ, Polepally Village, Jadcherla Mandal, Mahabubnagar (District), Telangana, India 509301.

8. On information and belief, Hetero USA is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 1035 Centennial Avenue, Piscataway, New Jersey 08854.

### **JURISDICTION AND VENUE**

9. This is an action for patent infringement arising under the Patent Laws of the United States, 35 U.S.C. § 100 *et seq.*, including § 271(e)(2), and also including an action seeking declaratory judgment pursuant to the Declaratory Judgment Act, 28 U.S.C. §§ 2201-02 for patent infringement arising under 35 U.S.C. § 100 *et seq.*, including § 271(a)-(c).

10. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

11. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391 and 1400(b).

12. On information and belief, Defendants cooperate, collaborate, or act in concert for the purposes of manufacturing, selling, marketing, distributing, and importing generic drug products in New Jersey and throughout the United States.

13. On information and belief, Hetero Labs has substantial, continuous, and systematic contacts with New Jersey.

14. On information and belief, Hetero Labs develops, manufactures, markets, and distributes pharmaceutical products, including generic pharmaceutical products, for sale in the State of New Jersey and throughout the United States.

15. On information and belief, Hetero Labs, alone or together with Hetero USA, has committed, or aided, abetted, actively induced, contributed to, or participated in the commission of an act of patent infringement under 35 U.S.C. § 271(e)(2) that has led or will lead to foreseeable harm and injury to Plaintiffs throughout the United States, including in New Jersey.

16. On information and belief, Hetero Labs consented to jurisdiction, did not contest jurisdiction, or asserted counterclaims in New Jersey in one or more prior litigations, for example: *Celgene Corp. v. Hetero Labs Ltd.*, No. 2-20-cv-14389; *Celgene Corp. v. Hetero Labs Ltd.*, No. 2-19-cv-15449; *Celgene Corp. v. Hetero Labs Ltd.*, No. 2-19-cv-05797; *Celgene Corp. v. Hetero Labs Ltd.*, No. 2-18-cv-17463; *Celgene Corp. v. Hetero Labs Ltd.*, No. 2-18-cv-14111; *Aragon Pharms., Inc. v. Hetero Labs Ltd. Unit V*, No. 2-22-cv-03212, *Aragon Pharms., Inc. v. Hetero Labs Ltd. Unit V*, No. 2-24-cv-06784.

17. This Court has personal jurisdiction over Hetero Labs by virtue of, among other things, (1) its continuous and systematic contacts with New Jersey; (2) its acts of patent infringement that will result in foreseeable harm in New Jersey; (3) its sale of a substantial

volume of prescription drugs in New Jersey; and (4) its conduct by and through, and in concert with, Hetero USA.

18. This Court has personal jurisdiction over Hetero Labs because, *inter alia*, this action arises from actions of Hetero Labs directed toward New Jersey. For example, Defendants submitted the ANDA seeking approval to commercially manufacture, use, sell, offer for sale, or import the Proposed ANDA Product prior to the expiration of the Patents-In-Suit. If FDA approval is obtained, the Proposed ANDA Product would be sold in New Jersey, causing injury to Plaintiffs in New Jersey.

19. Exercising personal jurisdiction over Hetero Labs in this district would not be unreasonable given Hetero Labs' contacts in this district and the interest in this district of resolving disputes related to products to be sold herein.

20. In the alternative, this Court has personal jurisdiction over Hetero Labs because the requirements of Federal Rule of Civil Procedure 4(k)(2)(A) are met: (a) Plaintiffs' claims arise under federal law; (b) Hetero Labs is a foreign defendant not subject to personal jurisdiction in the courts of any State; and (c) Hetero Labs has sufficient contacts with the United States as a whole, including, but not limited to, filing Abbreviated New Drug Applications with the FDA and manufacturing and selling generic pharmaceutical products that are distributed throughout the United States, such that this Court's exercise of jurisdiction over Hetero Labs satisfies due process, and is consistent with the United States Constitution and Laws.

21. Venue is proper under 28 U.S.C. § 1391(c)(3) because Hetero Labs is a foreign corporation.

22. On information and belief, Hetero USA has substantial, continuous, and systematic contacts with New Jersey.

23. On information and belief, Hetero USA develops, manufactures, markets, and distributes pharmaceutical products, including generic pharmaceutical products, for sale in the State of New Jersey and throughout the United States.

24. On information and belief, Hetero USA has substantial, continuous, and systematic contacts with New Jersey, including that it is registered to do business in New Jersey (Entity Id. No. 0400362826) and is registered as a drug wholesaler in New Jersey (Registration No. 5004050).

25. On information and belief, Hetero USA has a regular and established business at 1035 Centennial Avenue, Piscataway, New Jersey 08854 and has registered this address with the New Jersey Department of Health.

26. On information and belief, Hetero USA, alone or together with Hetero Labs, has committed, or aided, abetted, actively induced, contributed to, or participated in the commission of an act of patent infringement under 35 U.S.C. § 271(e)(2) that has led or will lead to foreseeable harm and injury to Plaintiffs throughout the United States, including in New Jersey.

27. On information and belief, Hetero USA consented to jurisdiction, did not contest jurisdiction, or asserted counterclaims in New Jersey in one or more prior litigations, for example: *Celgene Corp. v. Hetero Labs Ltd.*, No. 2-20-cv-14389; *Celgene Corp. v. Hetero Labs Ltd.*, No. 2-19-cv-15449; *Celgene Corp. v. Hetero Labs Ltd.*, No. 2-19-cv-05797; *Celgene Corp. v. Hetero Labs Ltd.*, No. 2-18-cv-17463; *Celgene Corp. v. Hetero Labs Ltd.*, No. 2-18-cv-14111; *Aragon Pharms., Inc. v. Hetero Labs Ltd. Unit V*, No. 2-22-cv-03212, *Aragon Pharms., Inc. v. Hetero Labs Ltd. Unit V*, No. 2-24-cv-06784.

28. This Court has personal jurisdiction over Hetero USA by virtue of, among other things, (1) its continuous and systematic contacts with New Jersey; (2) its acts of patent

infringement that will result in foreseeable harm in New Jersey; (3) its sale of a substantial volume of prescription drugs in New Jersey; and (4) its conduct by and through, and in concert with, Hetero Labs.

29. This Court has personal jurisdiction over Hetero USA because, *inter alia*, this action arises from actions of Hetero USA directed toward New Jersey. For example, Defendants submitted the ANDA seeking approval to commercially manufacture, use, sell, offer for sale, or import the Proposed ANDA Product prior to the expiration of the Patents-In-Suit. If FDA approval is obtained, the Proposed ANDA Product would be sold in New Jersey, causing injury to Plaintiffs in New Jersey.

30. Exercising personal jurisdiction over Hetero USA in this district would not be unreasonable given Hetero USA's contacts in this district and the interest in this district of resolving disputes related to products to be sold herein.

31. On information and belief, Hetero USA has committed an act of infringement in this judicial district by submitting the ANDA with the FDA on or about March 20, 2025.

32. On information and belief, Defendants are cooperating, collaborating, or acting in concert with each other with respect to formulating, manufacturing, packaging, marketing, or selling with respect to the Proposed ANDA Product.

33. On information and belief, Hetero USA has committed acts or caused acts to be committed in preparation for and submission of the ANDA in this judicial district.

34. On information and belief, Hetero USA will directly benefit if the ANDA is approved by participating in the distribution, offer for sale, or sale of the Proposed ANDA Product.

35. Venue is proper under 28 U.S.C. § 1400(b) because Hetero USA has committed an act of infringement and has a regular and established place of business in this judicial district.

**ERLEADA®**

36. JBI holds approved New Drug Application No. 210951 for apalutamide, which is prescribed and sold as Erleada®.

37. On information and belief, Defendants know that JBI holds approved New Drug Application No. 210951.

38. Erleada® is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Erleada® is supplied as 60 mg and 240 mg tablets for oral administration containing the active pharmaceutical ingredient apalutamide.

39. The International Union of Pure and Applied Chemistry (IUPAC) name for apalutamide is 4-[7-(6-Cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.

**THE PATENTS-IN-SUIT**

40. On May 21, 2013, the 507 Patent, titled “Androgen Receptor Modulator for the Treatment of Prostate Cancer and Androgen Receptor-Associated Diseases” was duly and legally issued to Regents as assignee. A copy of the 507 Patent is attached as Exhibit A.

41. On August 12, 2014, the 689 Patent, titled “Androgen Receptor Modulator for the Treatment of Prostate Cancer and Androgen Receptor-Associated Diseases” was duly and legally issued to Regents as assignee. A copy of the 689 Patent is attached as Exhibit B.



42. On July 12, 2016, the 159 Patent, titled “Substituted Diazaspiroalkanes as Androgen Receptor Modulators” was duly and legally issued to Regents as assignee. A copy of the 159 Patent is attached as Exhibit C.

43. On June 5, 2018, the 261 Patent, titled “Substituted Diazaspiroalkanes as Androgen Receptor Modulators” was duly and legally issued to Regents as assignee. A copy of the 261 Patent is attached as Exhibit D.

44. On November 1, 2016, the 663 Patent, titled “Crystalline Forms of an Androgen Receptor Modulator” was duly and legally issued to Aragon and Sloan-Kettering as assignees. A copy of the 663 Patent is attached as Exhibit E.

45. On February 6, 2018, the 054 Patent, titled “Anti-androgens for the Treatment of Non-metastatic Castrate-resistant Prostate Cancer” was duly and legally issued to Aragon as assignee. A copy of the 054 Patent is attached as Exhibit F.

46. On January 3, 2023, the RE353 Patent, titled “Anti-androgens for the Treatment of Non-metastatic Castrate-resistant Prostate Cancer” was duly and legally issued to Aragon as assignee. A copy of the RE353 Patent is attached as Exhibit G.

47. On December 1, 2020, the 888 Patent, titled “Anti-androgens for the Treatment of Non-metastatic Castrate-resistant Prostate Cancer” was duly and legally issued to Aragon as assignee. A copy of the 888 Patent is attached as Exhibit H.

48. On July 7, 2020, the 508 Patent, titled “Anti-androgens for the Treatment of Non-metastatic Castrate-resistant Prostate Cancer” was duly and legally issued to Aragon as assignee. A copy of the 508 Patent is attached as Exhibit I.

49. On April 23, 2024, the 952 Patent, titled “Anti-Androgens for the Treatment of Metastatic Castration-Sensitive Prostate Cancer” was duly and legally issued to Aragon as assignee. A copy of the 952 Patent is attached as Exhibit J.

50. Pursuant to 21 U.S.C. § 355(b)(1), the Patents-In-Suit are listed in the FDA publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (also known as the “Orange Book”) as covering Erleada<sup>®</sup>.

51. On information and belief, Defendants know that the Patents-In-Suit are listed in the Orange Book as covering Erleada<sup>®</sup>.

#### **DEFENDANTS’ NOTICE LETTERS AND THE ANDA**

52. By letter dated May 8, 2025, addressed to JBI, Sloan-Kettering, Aragon, and Regents (“2025 Notice Letter”), Defendants notified Plaintiffs that they had submitted ANDA No. 220525 to the FDA under § 505(j)(2) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)). The 2025 Notice Letter stated that the ANDA seeks the FDA approval necessary to engage in activities that constitute or require the commercial manufacture, use, sale, offer for sale in, or importation into the United States, of the Proposed ANDA Product, described in the 2025 Notice Letter as “Apalutamide Tablets; Oral, 240 mg” prior to the expiration of the 507 Patent, the 689 Patent, the 159 Patent, the 261 Patent, the 663 Patent, the 054 Patent, the RE353 Patent, the 888 Patent, the 508 Patent, and the 952 Patent.

53. The 2025 Notice Letter stated that Defendants had received a Paragraph IV acknowledgement letter from the FDA.

54. The ANDA includes a Paragraph IV Certification that the claims of the 507 Patent, the 689 Patent, the 159 Patent, the 261 Patent, the 663 Patent, the 054 Patent, the RE353

Patent, the 888 Patent, the 508 Patent, and the 952 Patent are invalid, unenforceable, or not infringed.

55. The 2025 Notice Letter included an Offer for Confidential Access (“OCA”) to the ANDA. The parties agreed on revised terms for the OCA. On June 6, 2025, Defendants produced documents that Defendants purported to be the ANDA.

56. Defendants have actual knowledge of each of the Patents-In-Suit, at least as shown by the discussion of the Orange Book listing for Erleada<sup>®</sup> in the 2025 Notice Letter. Additionally, in prior proceedings involving Defendants’ proposed generic version of Erleada<sup>®</sup> 60 mg tablets, Plaintiffs asserted infringement of the 507 Patent, the 663 Patent, the 054 Patent, the RE353 Patent, the 508 Patent, and the 888 Patent in *Aragon Pharms., Inc. v. Hetero Labs Ltd. Unit V*, No. 2-22-cv-03212 (D.N.J.) and Plaintiffs asserted infringement of the 689 Patent, the 159 Patent, the 261 Patent in *Aragon Pharms., Inc. v. Hetero Labs Ltd. Unit V*, No. 2-24-cv-06784 (D.N.J.).

57. On information and belief, Defendants seek to obtain FDA approval to manufacture, use, import, offer to sell, and sell its Proposed ANDA Product in the United States before the expiration of the Patents-In-Suit.

58. Plaintiffs are commencing this action within 45 days of the date of receipt of the 2025 Notice Letter.

### **COUNT I – CLAIM FOR INFRINGEMENT OF THE 507 PATENT**

59. Plaintiffs re-allege each of the foregoing paragraphs as if fully set forth herein.

60. An actual controversy exists between the parties as to whether Defendants’ proposed sale of the Proposed ANDA Product infringes the claims of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22.

61. On information and belief, because the Proposed ANDA Product contains apalutamide, the Proposed ANDA Product and the use of the Proposed ANDA Product infringe at least claims 1, 2, 3, 11, 19, and 22 of the 507 Patent.

62. On information and belief, the Proposed ANDA Product infringes at least claims 1 and 22 of the 507 Patent because it contains the compound apalutamide.

63. On information and belief, the Proposed ANDA Product infringes at least claims 2 and 11 of the 507 Patent because it is a pharmaceutical composition comprising a therapeutically effective amount of the compound apalutamide and a pharmaceutically acceptable carrier, diluent, or adjuvant.

64. On information and belief, the use of the Proposed ANDA Product will infringe at least claims 3 and 19 of the 507 Patent because physicians and/or patients will practice a method for treating a hyperproliferative disorder, specifically prostate cancer, said method comprising administering, causing to be administered, or directing the administration of the compound apalutamide to a subject, specifically a patient, in need of such treatment, thereby treating the prostate cancer.

65. On information and belief, Defendants will induce infringement of at least claims 3 and 19 of the 507 Patent by actively inducing the use of the Proposed ANDA Product to practice a method for treating a hyperproliferative disorder, specifically prostate cancer, said method comprising administering, causing to be administered, or directing the administration of the compound apalutamide to a subject, specifically a patient, in need of such treatment, thereby treating the prostate cancer.

66. On information and belief, if the FDA approves the ANDA, Defendants will sell or offer to sell the Proposed ANDA Product specifically labeled for use in practicing the claims

of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22, wherein the Proposed ANDA Product is a material part of the claimed invention, wherein Defendants know that physicians will prescribe and patients will use the Proposed ANDA Product in accordance with the instructions or label provided by Defendants in practicing the claims of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22, and wherein the Proposed ANDA Product is not a staple article or commodity of commerce suitable for substantial non-infringing use.

67. The 2025 Notice Letter purports to include a Notice of Certification for the ANDA under 37 C.F.R. § 314.95(c)(6) as to the 507 Patent. The 2025 Notice Letter did not include a detailed and supported statement of allegations of invalidity, unenforceability, or non-infringement for every claim of the 507 Patent.

68. On information and belief, Defendants have actual knowledge of the 507 Patent, at least as shown by the 2025 Notice Letter.

69. On information and belief, under 35 U.S.C. § 271(e)(2)(A), Defendants have infringed the claims of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22, by submitting or causing to be submitted to the FDA, the ANDA seeking approval to manufacture, use, import, offer to sell or sell the Proposed ANDA Product before the expiration date of the 507 Patent.

70. On information and belief, the Proposed ANDA Product and its use, if approved and marketed, will infringe, either literally or under the doctrine of equivalents, at least one claim of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22, under at least one of 35 U.S.C. § 271(a), (b), or (c).

71. On information and belief, the manufacture, use, import, offer to sell, or sale of the Proposed ANDA Product will directly infringe the claims of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22.

72. On information and belief, physicians and/or patients will directly infringe the claims of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22, by the use of the Proposed ANDA Product upon approval.

73. On information and belief, upon approval, Defendants will take active steps to encourage the use of the Proposed ANDA Product by physicians and/or patients with the knowledge and intent that the Proposed ANDA Product will be used by physicians and/or patients, in a manner that infringes the claims of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22, for the pecuniary benefit of Defendants.

74. On information and belief, Defendants specifically intend the Proposed ANDA Product to be used in a manner that infringes the claims of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22. On information and belief, Defendants will actively induce the infringement of the claims of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22.

75. On information and belief, the Proposed ANDA Product is specifically designed for use in a manner that infringes the claims of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22. On information and belief, Defendants will thus contribute to the infringement of the claims of the 507 Patent, including at least claims 1, 2, 3, 11, 19, and 22.

76. On information and belief, the actions described in this Complaint relating to the ANDA and the 507 Patent were done by and for the benefit of Defendants.


77. Plaintiffs will be irreparably harmed by these infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

**COUNT II – CLAIM FOR INFRINGEMENT OF THE 689  
PATENT**

78. Plaintiffs re-allege each of the foregoing paragraphs as if fully set forth herein.

79. An actual controversy exists between the parties as to whether Defendants' proposed sale of the Proposed ANDA Product infringes the claims of the 689 Patent, including at least claim 2.

80. On information and belief, the Proposed ANDA Product contains apalutamide, which is a compound having the formula:



, which will infringe the genus of compounds claimed in at least claim 2 of the 689 Patent.

81. On information and belief, the use of the Proposed ANDA Product will infringe at least claim 2 of the 689 Patent because physicians and/or patients will practice a method for treating prostate cancer in a subject, specifically a patient, said method comprising administering, causing to be administered, or directing the administration of the compound apalutamide to the patient in need of such treatment.

82. On information and belief, Defendants will induce infringement of at least claim 2 of the 689 Patent by actively inducing the use of the Proposed ANDA Product to practice a method for treating prostate cancer in a subject, specifically a patient, said method comprising administering, causing to be administered, or directing the administration of the compound apalutamide to the patient in need of such treatment.

83. On information and belief, if the FDA approves the ANDA, Defendants will sell or offer to sell the Proposed ANDA Product specifically labeled for use in practicing the claims

of the 689 Patent, including at least claim 2, wherein the Proposed ANDA Product is a material part of the claimed invention, wherein Defendants know that physicians will prescribe and patients will use the Proposed ANDA Product in accordance with the instructions or label provided by Defendants in practicing the claims of the 689 Patent, including at least claim 2, and wherein the Proposed ANDA Product is not a staple article or commodity of commerce suitable for substantial non-infringing use.

84. The 2025 Notice Letter purports to include a Notice of Certification for the ANDA under 37 C.F.R. § 314.95(c)(6) as to the 689 Patent. The 2025 Notice Letter did not include a detailed and supported statement of allegations of invalidity, unenforceability, or non-infringement for every claim of the 689 Patent.

85. On information and belief, Defendants have actual knowledge of 689 Patent, at least as shown by the 2025 Notice Letter.

86. On information and belief, under 35 U.S.C. § 271(e)(2)(A), Defendants have infringed the claims of the 689 Patent, including at least claim 2, by submitting or causing to be submitted to the FDA, the ANDA seeking approval to manufacture, use, import, offer to sell or sell the Proposed ANDA Product before the expiration date of the 689 Patent.

87. On information and belief, the use of the Proposed ANDA Product, if approved and marketed, will infringe, either literally or under the doctrine of equivalents, at least one claim of the 689 Patent, including at least claim 2, under at least one of 35 U.S.C. § 271(a), (b), or (c).

88. On information and belief, the manufacture, use, import, offer to sell, or sale of the Proposed ANDA Product will directly infringe the claims of the 689 Patent, including at least claim 2.



89. On information and belief, physicians and/or patients will directly infringe the claims of the 689 Patent, including at least claim 2, by the use of the Proposed ANDA Product upon approval.

90. On information and belief, upon approval, Defendants will take active steps to encourage the use of the Proposed ANDA Product by physicians and/or patients with the knowledge and intent that the Proposed ANDA Product will be used by physicians and/or patients, in a manner that infringes the claims of the 689 Patent, including at least claim 2, for the pecuniary benefit of Defendants.

91. On information and belief, Defendants specifically intend the Proposed ANDA Product to be used in a manner that infringes the claims of the 689 Patent, including at least claim 2. On information and belief, Defendants will actively induce the infringement of the claims of the 689 Patent, including at least claim 2.

92. On information and belief, the Proposed ANDA Product is specifically designed for use in a manner that infringes the claims of the 689 Patent, including at least claim 2. On information and belief, Defendants will thus contribute to the infringement of the claims of the 689 Patent, including at least claim 2.

93. On information and belief, the actions described in this Complaint relating to the ANDA and the 689 Patent were done by and for the benefit of Defendants.

94. Plaintiffs will be irreparably harmed by these infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.


### **COUNT III – CLAIM FOR INFRINGEMENT OF THE 159 PATENT**

95. Plaintiffs re-allege each of the foregoing paragraphs as if fully set forth herein.

96. An actual controversy exists between the parties as to whether Defendants' proposed sale of the Proposed ANDA Product infringes the claims of the 159 Patent, including at least claims 1, 12, and 17.

97. On information and belief, because the Proposed ANDA Product contains apalutamide, the Proposed ANDA Product and the use of the Proposed ANDA Product infringe at least claims 1, 12, and 17 of the 159 Patent.

98. On information and belief, the Proposed ANDA Product contains apalutamide, which is a compound having the formula:



, which will infringe the genus of compounds claimed in at least claim 1 of the 159 Patent.

99. On information and belief, the Proposed ANDA Product infringes at least claims 12 and 17 of the 159 Patent because it is a pharmaceutical composition comprising a therapeutically effective amount of the compound apalutamide formulated in an oral dosage form and a pharmaceutically acceptable carrier, diluent, or adjuvant.

100. On information and belief, if the FDA approves the ANDA, Defendants will sell or offer to sell the Proposed ANDA Product specifically labeled for use in practicing the claims of the 159 Patent, including at least claims 1, 12, and 17, wherein the Proposed ANDA Product is a material part of the claimed invention, wherein Defendants know that physicians will prescribe and patients will use the Proposed ANDA Product in accordance with the instructions or label provided by Defendants in practicing the claims of the 159 Patent, including at least

claims 1, 12, and 17, and wherein the Proposed ANDA Product is not a staple article or commodity of commerce suitable for substantial non-infringing use.

101. The 2025 Notice Letter purports to include a Notice of Certification for the ANDA under 37 C.F.R. § 314.95(c)(6) as to the 159 Patent. The 2025 Notice Letter did not include a detailed and supported statement of allegations of invalidity, unenforceability, or non-infringement for every claim of the 159 Patent.

102. On information and belief, Defendants have actual knowledge of the 159 Patent, at least as shown by the 2025 Notice Letter.

103. On information and belief, under 35 U.S.C. § 271(e)(2)(A), Defendants have infringed the claims of the 159 Patent, including at least claims 1, 12, and 17, by submitting or causing to be submitted to the FDA, the ANDA seeking approval to manufacture, use, import, offer to sell or sell the Proposed ANDA Product before the expiration date of the 159 Patent.

104. On information and belief, the Proposed ANDA Product and its use, if approved and marketed, will infringe, either literally or under the doctrine of equivalents, at least one claim of the 159 Patent, including at least claims 1, 12, and 17, under at least one of 35 U.S.C. § 271(a), (b), or (c).

105. On information and belief, the manufacture, use, import, offer to sell, or sale of the Proposed ANDA Product will directly infringe the claims of the 159 Patent, including at least claims 1, 12, and 17.

106. On information and belief, physicians and/or patients will directly infringe the claims of the 159 Patent, including at least claims 1, 12, and 17, by the use of the Proposed ANDA Product upon approval.

107. On information and belief, upon approval, Defendants will take active steps to encourage the use of the Proposed ANDA Product by physicians and/or patients with the knowledge and intent that the Proposed ANDA Product will be used by physicians and/or patients, in a manner that infringes the claims of the 159 Patent, including at least claims 1, 12, and 17, for the pecuniary benefit of Defendants.

108. On information and belief, Defendants specifically intend the Proposed ANDA Product to be used in a manner that infringes the claims of the 159 Patent, including at least claims 1, 12, and 17. On information and belief, Defendants will actively induce the infringement of the claims of the 159 Patent, including at least claims 1, 12, and 17.

109. On information and belief, the Proposed ANDA Product is specifically designed for use in a manner that infringes the claims of the 159 Patent, including at least claims 1, 12, and 17. On information and belief, Defendants will thus contribute to the infringement of the claims of the 159 Patent, including at least claims 1, 12, and 17.

110. On information and belief, the actions described in this Complaint relating to the ANDA and the 159 Patent were done by and for the benefit of Defendants.


111. Plaintiffs will be irreparably harmed by these infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

#### **COUNT IV – CLAIM FOR INFRINGEMENT OF THE 261 PATENT**

112. Plaintiffs re-allege each of the foregoing paragraphs as if fully set forth herein.

113. An actual controversy exists between the parties as to whether Defendants' proposed sale of the Proposed ANDA Product infringes the claims of the 261 Patent, including at least claims 10 and 12.

114. On information and belief, the Proposed ANDA Product contains apalutamide, which is a compound having the formula:



. Thus, the Proposed ANDA Product and the use of the Proposed ANDA Product will infringe at least claims 10 and 12 of the 261 Patent.

115. On information and belief, the Proposed ANDA Product infringes at least claims 10 and 12 of the 261 Patent because it is a tablet comprising the compound apalutamide in a range of from 0.0005 to 500 mg and a pharmaceutically acceptable carrier, diluent, or adjuvant.

116. On information and belief, if the FDA approves the ANDA, Defendants will sell or offer to sell the Proposed ANDA Product specifically labeled for use in practicing the claims of the 261 Patent, including at least claims 10 and 12, wherein the Proposed ANDA Product is a material part of the claimed invention, wherein Defendants know that physicians will prescribe and patients will use the Proposed ANDA Product in accordance with the instructions or label provided by Defendants in practicing the claims of the 261 Patent, including at least claims 10 and 12, and wherein the Proposed ANDA Product is not a staple article or commodity of commerce suitable for substantial non-infringing use.

117. The 2025 Notice Letter purports to include a Notice of Certification for the ANDA under 37 C.F.R. § 314.95(c)(6) as to the 261 Patent. The 2025 Notice Letter did not include a detailed and supported statement of allegations of invalidity, unenforceability, or non-infringement for every claim of the 261 Patent.

118. On information and belief, Defendants have actual knowledge of the 261 Patent, at least as shown by the 2025 Notice Letter.

119. On information and belief, under 35 U.S.C. § 271(e)(2)(A), Defendants have infringed the claims of the 261 Patent, including at least claims 10 and 12, by submitting or causing to be submitted to the FDA, the ANDA seeking approval to manufacture, use, import, offer to sell or sell the Proposed ANDA Product before the expiration date of the 261 Patent.

120. On information and belief, the Proposed ANDA Product and its use, if approved and marketed, will infringe, either literally or under the doctrine of equivalents, at least one claim of the 261 Patent, including at least claims 10 and 12, under at least one of 35 U.S.C. § 271(a), (b), or (c).

121. On information and belief, the manufacture, use, import, offer to sell, or sale of the Proposed ANDA Product will directly infringe the claims of the 261 Patent, including at least claims 10 and 12.

122. On information and belief, physicians and/or patients will directly infringe the claims of the 261 Patent, including at least claims 10 and 12, by the use of the Proposed ANDA Product upon approval.

123. On information and belief, upon approval, Defendants will take active steps to encourage the use of the Proposed ANDA Product by physicians and/or patients with the knowledge and intent that the Proposed ANDA Product will be used by physicians and/or patients, in a manner that infringes the claims of the 261 Patent, including at least claims 10 and 12, for the pecuniary benefit of Defendants.

124. On information and belief, Defendants specifically intend the Proposed ANDA Product to be used in a manner that infringes the claims of the 261 Patent, including at least claims 10 and 12. On information and belief, Defendants will actively induce the infringement of the claims of the 261 Patent, including at least claims 10 and 12.

125. On information and belief, the Proposed ANDA Product is specifically designed for use in a manner that infringes the claims of the 261 Patent, including at least claims 10 and 12. On information and belief, Defendants will thus contribute to the infringement of the claims of the 261 Patent, including at least claims 10 and 12.

126. On information and belief, the actions described in this Complaint relating to the ANDA and the 261 Patent were done by and for the benefit of Defendants.

127. Plaintiffs will be irreparably harmed by these infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

**COUNT V – CLAIM FOR INFRINGEMENT OF THE 663  
PATENT**

128. Plaintiffs re-allege each of the foregoing paragraphs as if fully set forth herein.

129. An actual controversy exists between the parties as to whether Defendants' proposed sale of the Proposed ANDA Product infringes the claims of the 663 Patent, including at least claims 1, 13, and 17.

130. On information and belief, because the Proposed ANDA Product and the drug substance in and used for the Proposed ANDA Product contain some amount of crystalline Form B of apalutamide, the Proposed ANDA Product and the drug substance infringe at least claims 1, 13, and 17 of the 663 Patent.

131. On information and belief, the Proposed ANDA Product and the drug substance in and used for the Proposed ANDA Product infringe at least claim 1 of the 663 Patent because they contain crystalline Form B of apalutamide that is characterized as having at least one of an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 2 of the 663 Patent or an X-ray powder diffraction (XRPD) pattern with characteristic peaks at  $12.1 \pm 0.1^\circ$  2-Theta,  $16.0 \pm 0.1^\circ$  2-Theta,  $16.7 \pm 0.1^\circ$  2-Theta,  $20.1 \pm 0.1^\circ$  2-Theta,  $20.3 \pm 0.1^\circ$  2-Theta.

132. On information and belief, the Proposed ANDA Product and the drug substance in and used for the Proposed ANDA Product infringe at least claim 13 of the 663 Patent because they are a pharmaceutical composition comprising apalutamide and at least one additional ingredient selected from pharmaceutically acceptable carriers, diluents and excipients, in which the apalutamide in the composition comprises the crystalline Form B that is characterized as having at least one of an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 2 of the 663 Patent or an X-ray powder diffraction (XRPD) pattern with characteristic peaks at  $12.1 \pm 0.1^\circ$  2-Theta,  $16.0 \pm 0.1^\circ$  2-Theta,  $16.7 \pm 0.1^\circ$  2-Theta,  $20.1 \pm 0.1^\circ$  2-Theta,  $20.3 \pm 0.1^\circ$  2-Theta.

133. On information and belief, the use of the Proposed ANDA Product and the drug substance in and used for the Proposed ANDA Product will infringe at least claim 17 of the 663 Patent because physicians and/or patients will practice a method of treating prostate cancer in a mammal, specifically a patient, said method comprising administering, causing to be administered, or directing the administration of a pharmaceutical composition comprising apalutamide and at least one additional ingredient selected from pharmaceutically acceptable carriers, diluents and excipients, in which the apalutamide in the composition comprises the crystalline Form B that is characterized as having at least one of an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 2 of the 663 Patent or an X-ray powder diffraction (XRPD) pattern with characteristic peaks at  $12.1 \pm 0.1^\circ$  2-Theta,  $16.0 \pm 0.1^\circ$  2-Theta,  $16.7 \pm 0.1^\circ$  2-Theta,  $20.1 \pm 0.1^\circ$  2-Theta,  $20.3 \pm 0.1^\circ$  2-Theta to the patient in need of such treatment.

134. On information and belief, Defendants will induce infringement of at least claim 17 of the 663 Patent by actively inducing the use of the Proposed ANDA Product to practice a



method of treating prostate cancer in a mammal, specifically a patient, said method comprising administering, causing to be administered, or directing the administration of a pharmaceutical composition comprising apalutamide and at least one additional ingredient selected from pharmaceutically acceptable carriers, diluents and excipients, in which the apalutamide in the composition comprises the crystalline Form B that is characterized as having at least one of an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 2 of the 663 Patent or an X-ray powder diffraction (XRPD) pattern with characteristic peaks at  $12.1 \pm 0.1^\circ$  2-Theta,  $16.0 \pm 0.1^\circ$  2-Theta,  $16.7 \pm 0.1^\circ$  2-Theta,  $20.1 \pm 0.1^\circ$  2-Theta,  $20.3 \pm 0.1^\circ$  2-Theta to the patient in need of such treatment.

135. On information and belief, if the FDA approves the ANDA, Defendants will sell or offer to sell the Proposed ANDA Product specifically labeled for use in practicing the claims of the 663 Patent, including at least claims 1, 13, and 17, wherein the Proposed ANDA Product is a material part of the claimed invention, wherein Defendants know that physicians will prescribe and patients will use the Proposed ANDA Product in accordance with the instructions or label provided by Defendants in practicing the claims of the 663 Patent, including at least claims 1, 13, and 17, and wherein the Proposed ANDA Product is not a staple article or commodity of commerce suitable for substantial non-infringing use.

136. The 2025 Notice Letter purports to include a Notice of Certification for the ANDA under 37 C.F.R. § 314.95(c)(6) as to the 663 Patent. The 2025 Notice Letter did not include a detailed and supported statement of allegations of invalidity, unenforceability, or non-infringement for every claim of the 663 Patent.

137. On information and belief, Defendants have actual knowledge of the 663 Patent, at least as shown by the 2025 Notice Letter.

138. On information and belief, under 35 U.S.C. § 271(e)(2)(A), Defendants have infringed the claims of the 663 Patent, including at least claims 1, 13, and 17, by submitting or causing to be submitted to the FDA, the ANDA seeking approval to manufacture, use, import, offer to sell or sell the Proposed ANDA Product before the expiration date of the 663 Patent.

139. On information and belief, the Proposed ANDA Product and its use, if approved and marketed, will infringe, either literally or under the doctrine of equivalents, at least one claim of the 663 Patent, including at least claims 1, 13, and 17, under at least one of 35 U.S.C. § 271(a), (b), or (c).

140. On information and belief, the manufacture, use, import, offer to sell, or sale of the Proposed ANDA Product will directly infringe the claims of the 663 Patent, including at least claims 1, 13, and 17.

141. On information and belief, physicians and/or patients will directly infringe the claims of the 663 Patent, including at least claims 1, 13, and 17, by the use of the Proposed ANDA Product upon approval.

142. On information and belief, upon approval, Defendants will take active steps to encourage the use of the Proposed ANDA Product by physicians and/or patients with the knowledge and intent that the Proposed ANDA Product will be used by physicians and/or patients, in a manner that infringes the claims of the 663 Patent, including at least claims 1, 13, and 17, for the pecuniary benefit of Defendants.

143. On information and belief, Defendants specifically intend the Proposed ANDA Product to be used in a manner that infringes the claims of the 663 Patent, including at least claims 1, 13, and 17. On information and belief, Defendants will actively induce the infringement of the claims of the 663 Patent, including at least claims 1, 13, and 17.

144. On information and belief, the Proposed ANDA Product is specifically designed for use in a manner that infringes the claims of the 663 Patent, including at least claims 1, 13, and 17. On information and belief, Defendants will thus contribute to the infringement of the claims of the 663 Patent, including at least claims 1, 13, and 17.

145. On information and belief, the actions described in this Complaint relating to the ANDA and the 663 Patent were done by and for the benefit of Defendants.

146. Plaintiffs will be irreparably harmed by these infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

#### **COUNT VI – CLAIM FOR INFRINGEMENT OF THE 054 PATENT**

147. Plaintiffs re-allege each of the foregoing paragraphs as if fully set forth herein.

148. An actual controversy exists between the parties as to whether Defendants' proposed sale of the Proposed ANDA Product infringes the claims of the 054 Patent, including at least claims 6 and 15.

149. On information and belief, the use of the Proposed ANDA Product will infringe at least claims 6 and 15 of the 054 Patent because physicians and/or patients will practice a method of treating non-metastatic castration-resistant prostate cancer in a male human, said method comprising administering, causing to be administered, or directing the administration of a therapeutically effective amount of an anti-androgen to a male human in need of such treatment, wherein the anti-androgen is apalutamide that is administered orally to the male human at a dose of about 240 mg per day.

150. On information and belief, Defendants will induce infringement of at least claims 6 and 15 of the 054 Patent by actively inducing the use of the Proposed ANDA Product to practice a method of treating non-metastatic castration-resistant prostate cancer in a male human,

said method comprising administering, causing to be administered, or directing the administration of a therapeutically effective amount of an anti-androgen to a male human in need of such treatment, wherein the anti-androgen is apalutamide that is administered orally to the male human at a dose of about 240 mg per day.

151. On information and belief, if the FDA approves the ANDA, Defendants will sell or offer to sell the Proposed ANDA Product specifically labeled for use in practicing the claims of the 054 Patent, including at least claims 6 and 15, wherein the Proposed ANDA Product is a material part of the claimed invention, wherein Defendants know that physicians will prescribe and patients will use the Proposed ANDA Product in accordance with the instructions or label provided by Defendants in practicing the claims of the 054 Patent, including at least claims 6 and 15, and wherein the Proposed ANDA Product is not a staple article or commodity of commerce suitable for substantial non-infringing use.

152. The 2025 Notice Letter purports to include a Notice of Certification for the ANDA under 37 C.F.R. § 314.95(c)(6) as to the 054 Patent. The 2025 Notice Letter did not include a detailed and supported statement of allegations of invalidity, unenforceability, or non-infringement for every claim of the 054 Patent.

153. On information and belief, Defendants have actual knowledge of the 054 Patent, at least as shown by the 2025 Notice Letter.

154. On information and belief, under 35 U.S.C. § 271(e)(2)(A), Defendants have infringed the claims of the 054 Patent, including at least claims 6 and 15, by submitting or causing to be submitted to the FDA, the ANDA seeking approval to manufacture, use, import, offer to sell or sell the Proposed ANDA Product before the expiration date of the 054 Patent.

155. On information and belief, the use of the Proposed ANDA Product, if approved and marketed, will infringe, either literally or under the doctrine of equivalents, at least one claim of the 054 Patent, including at least claims 6 and 15, under at least one of 35 U.S.C. § 271(a), (b), or (c).

156. On information and belief, physicians and/or patients will directly infringe the claims of the 054 Patent, including at least claims 6 and 15, by the use of the Proposed ANDA Product upon approval.

157. On information and belief, upon approval, Defendants will take active steps to encourage the use of the Proposed ANDA Product by physicians and/or patients with the knowledge and intent that the Proposed ANDA Product will be used by physicians and/or patients, in a manner that infringes the claims of the 054 Patent, including at least claims 6 and 15, for the pecuniary benefit of Defendants.

158. On information and belief, Defendants specifically intend the Proposed ANDA Product to be used in a manner that infringes the claims of the 054 Patent, including at least claims 6 and 15. On information and belief, Defendants will actively induce the infringement of the claims of the 054 Patent, including at least claims 6 and 15.

159. On information and belief, Defendants' Proposed ANDA Product is specifically designed for use in a manner that infringes the claims of the 054 Patent, including at least claims 6 and 15. On information and belief, Defendants will thus contribute to the infringement of the claims of the 054 Patent, including at least claims 6 and 15.

160. On information and belief, the actions described in this Complaint relating to the ANDA and the 054 Patent were done by and for the benefit of Defendants.

161. Plaintiffs will be irreparably harmed by these infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

**COUNT VII – CLAIM FOR INFRINGEMENT OF THE  
RE353 PATENT**

162. Plaintiffs re-allege each of the foregoing paragraphs as if fully set forth herein.

163. An actual controversy exists between the parties as to whether Defendants’ proposed sale of the Proposed ANDA Product infringes the claims of the RE353 Patent, including at least claims 1 and 19.

164. On information and belief, the use of the Proposed ANDA Product will infringe at least claims 1 and 19 of the RE353 Patent because physicians and/or patients will practice a method of treating a male human with non-metastatic castration-resistant prostate cancer, said method comprising administering, causing to be administered, or directing the administration of an anti-androgen at a dose of about 240 mg per day to a male human in need of such treatment, wherein the anti-androgen is apalutamide, wherein said method further comprises administering a gonadotropin releasing hormone (GnRH) agonist.

165. Defendants will induce infringement of at least claims 1 and 19 of the RE353 Patent by actively inducing the use of the Proposed ANDA Product to practice a method of treating a male human with non-metastatic castration-resistant prostate cancer, said method comprising administering, causing to be administered, or directing the administration of an anti-androgen at a dose of about 240 mg per day to a male human in need of such treatment, wherein the anti-androgen is apalutamide, wherein said method further comprises administering a gonadotropin releasing hormone (GnRH) agonist.

166. On information and belief, if the FDA approves the ANDA, Defendants will sell or offer to sell the Proposed ANDA Product specifically labeled for use in practicing the claims

of the RE353 Patent, including at least claims 1 and 19, wherein the Proposed ANDA Product is a material part of the claimed invention, wherein Defendants know that physicians will prescribe and patients will use the Proposed ANDA Product in accordance with the instructions or label provided by Defendants in practicing the claims of the RE353 Patent, including at least claims 1 and 19, and wherein the Proposed ANDA Product is not a staple article or commodity of commerce suitable for substantial non-infringing use.

167. The 2025 Notice Letter purports to include a Notice of Certification for the ANDA under 37 C.F.R. § 314.95(c)(6) as to the RE353 Patent. The 2025 Notice Letter did not include a detailed and supported statement of allegations of invalidity, unenforceability, or non-infringement for every claim of the RE353 Patent.

168. On information and belief, Defendants have actual knowledge of the RE353 Patent, at least as shown by the 2025 Notice Letter.

169. On information and belief, under 35 U.S.C. § 271(e)(2)(A), Defendants have infringed the claims of the RE353 Patent, including at least claims 1 and 19, by submitting or causing to be submitted to the FDA, the ANDA seeking approval to manufacture, use, import, offer to sell or sell the Proposed ANDA Product before the expiration date of the RE353 Patent.

170. On information and belief, the use of the Proposed ANDA Product, if approved and marketed, will infringe, either literally or under the doctrine of equivalents, at least one claim of the RE353 Patent, including at least claims 1 and 19, under at least one of 35 U.S.C. § 271(a), (b), or (c).

171. On information and belief, physicians and/or patients will directly infringe the claims of the RE353 Patent, including at least claims 1 and 19, by the use of the Proposed ANDA Product upon approval.

172. On information and belief, upon approval, Defendants will take active steps to encourage the use of the Proposed ANDA Product by physicians and/or patients with the knowledge and intent that the Proposed ANDA Product will be used by physicians and/or patients, in a manner that infringes the claims of the RE353 Patent, including at least claims 1 and 19, for the pecuniary benefit of Defendants.

173. On information and belief, Defendants specifically intend the Proposed ANDA Product to be used in a manner that infringes the claims of the RE353 Patent, including at least claims 1 and 19. On information and belief, Defendants will actively induce the infringement of the claims of the RE353 Patent, including at least claims 1 and 19.

174. On information and belief, Defendants' Proposed ANDA Product is specifically designed for use in a manner that infringes the claims of the RE353 Patent, including at least claims 1 and 19. On information and belief, Defendants will thus contribute to the infringement of the claims of the RE353 Patent, including at least claims 1 and 19.

175. On information and belief, the actions described in this Complaint relating to the ANDA and the RE353 Patent were done by and for the benefit of Defendants.

176. Plaintiffs will be irreparably harmed by these infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

### **COUNT VIII – CLAIM FOR INFRINGEMENT OF THE 888 PATENT**

177. Plaintiffs re-allege each of the foregoing paragraphs as if fully set forth herein.

178. An actual controversy exists between the parties as to whether Defendants' proposed sale of the Proposed ANDA Product infringes the claims of the 888 Patent, including at least claims 1 and 8.



179. On information and belief, the use of the Proposed ANDA Product will infringe at least claims 1 and 8 of the 888 Patent because physicians and/or patients will practice a method of treating non-metastatic castration-resistant prostate cancer in a male human, said method comprising administering, causing to be administered, or directing the administration of an anti-androgen at a dose of about 240 mg per day to a male human in need of such treatment, wherein the anti-androgen is apalutamide and wherein said method further comprises orchiectomy.

180. On information and belief, Defendants will induce infringement of at least claims 1 and 8 of the 888 Patent by actively inducing the use of the Proposed ANDA Product to practice a method of treating non-metastatic castration-resistant prostate cancer in a male human, said method comprising administering, causing to be administered, or directing the administration of an anti-androgen at a dose of about 240 mg per day to a male human in need of such treatment, wherein the anti-androgen is apalutamide and wherein said method further comprises orchiectomy.

181. On information and belief, if the FDA approves the ANDA, Defendants will sell or offer to sell the Proposed ANDA Product specifically labeled for use in practicing the claims of the 888 Patent, including at least claims 1 and 8, wherein the Proposed ANDA Product is a material part of the claimed invention, wherein Defendants know that physicians will prescribe and patients will use the Proposed ANDA Product in accordance with the instructions or label provided by Defendants in practicing the claims of the 888 Patent, including at least claims 1 and 8, and wherein the Proposed ANDA Product is not a staple article or commodity of commerce suitable for substantial non-infringing use.

182. The 2025 Notice Letter purports to include a Notice of Certification for the ANDA under 37 C.F.R. § 314.95(c)(6) as to the 888 Patent. The 2025 Notice Letter did not

include a detailed and supported statement of allegations of invalidity, unenforceability, or non-infringement for every claim of the 888 Patent.

183. On information and belief, Defendants have actual knowledge of the 888 Patent, at least as shown by the 2025 Notice Letter.

184. On information and belief, under 35 U.S.C. § 271(e)(2)(A), Defendants have infringed the claims of the 888 Patent, including at least claims 1 and 8, by submitting or causing to be submitted to the FDA, the ANDA seeking approval to manufacture, use, import, offer to sell or sell the Proposed ANDA Product before the expiration date of the 888 Patent.

185. On information and belief, the use of the Proposed ANDA Product, if approved and marketed, will infringe, either literally or under the doctrine of equivalents, at least one claim of the 888 Patent, including at least claims 1 and 8, under at least one of 35 U.S.C. § 271(a), (b), or (c).

186. On information and belief, physicians and/or patients will directly infringe the claims of the 888 Patent, including at least claims 1 and 8, by the use of the Proposed ANDA Product upon approval.

187. On information and belief, upon approval, Defendants will take active steps to encourage the use of the Proposed ANDA Product by physicians and/or patients with the knowledge and intent that the Proposed ANDA Product will be used by physicians and/or patients, in a manner that infringes the claims of the 888 Patent, including at least claims 1 and 8, for the pecuniary benefit of Defendants.

188. On information and belief, Defendants specifically intend the Proposed ANDA Product to be used in a manner that infringes the claims of the 888 Patent, including at least

claims 1 and 8. On information and belief, Defendants will actively induce the infringement of the claims of the 888 Patent, including at least claims 1 and 8.

189. On information and belief, Defendants' Proposed ANDA Product is specifically designed for use in a manner that infringes the claims of the 888 Patent, including at least claims 1 and 8. On information and belief, Defendants will thus contribute to the infringement of the claims of the 888 Patent, including at least claims 1 and 8.

190. On information and belief, the actions described in this Complaint relating to the ANDA and the 888 Patent were done by and for the benefit of Defendants.

191. Plaintiffs will be irreparably harmed by these infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

#### **COUNT IX – CLAIM FOR INFRINGEMENT OF THE 508 PATENT**

192. Plaintiffs re-allege each of the foregoing paragraphs as if fully set forth herein.

193. An actual controversy exists between the parties as to whether Defendants' proposed sale of the Proposed ANDA Product infringes the claims of the 508 Patent, including at least claims 1, 2, 5, and 7.

194. On information and belief, the use of the Proposed ANDA Product will infringe at least claims 1 and 2 of the 508 Patent because physicians and/or patients will practice a method of improving metastasis free survival in a male human with nonmetastatic castration-resistant prostate cancer, said method comprising administering, causing to be administered, or directing the administration of, to said male human, an approved drug product comprising apalutamide in combination with androgen deprivation therapy, wherein the median metastasis free survival is about 40.5 months.

195. On information and belief, Defendants will induce infringement of at least claims 1 and 2 of the 508 Patent by actively inducing the use of the Proposed ANDA Product to practice a method of improving metastasis free survival in a male human with nonmetastatic castration-resistant prostate cancer, said method comprising administering, causing to be administered, or directing the administration of, to said male human, an approved drug product comprising apalutamide in combination with androgen deprivation therapy, wherein the median metastasis free survival is about 40.5 months.

196. On information and belief, the use of the Proposed ANDA Product will infringe claims at least 5 and 7 of the 508 Patent because physicians and/or patients will practice a method of improving metastasis free survival in a male human with nonmetastatic castration-resistant prostate cancer, said method comprising administering, causing to be administered, or directing the administration of, to said male human, an approved drug product comprising apalutamide in combination with androgen deprivation therapy, wherein a drug product label for a reference listed drug for such approved drug product comprises metastasis free survival data, wherein the metastasis free survival data for apalutamide in combination with androgen deprivation therapy arm has a median of about 40.5 months.

197. On information and belief, Defendants will induce infringement of at least claims 5 and 7 of the 508 Patent by actively inducing the use of the Proposed ANDA Product as a method of improving metastasis free survival in a male human with nonmetastatic castration-resistant prostate cancer, said method comprising administering, causing to be administered, or directing the administration of, to said male human, an approved drug product comprising apalutamide in combination with androgen deprivation therapy, wherein a drug product label for a reference listed drug for such approved drug product comprises metastasis

free survival data, wherein the metastasis free survival data for apalutamide in combination with androgen deprivation therapy arm has a median of about 40.5 months.

198. On information and belief, if the FDA approves the ANDA, Defendants will sell or offer to sell the Proposed ANDA Product specifically labeled for use in practicing the claims of the 508 Patent, including at least claims 1, 2, 5, and 7, wherein the Proposed ANDA Product is a material part of the claimed invention, wherein Defendants know that physicians will prescribe and patients will use the Proposed ANDA Product in accordance with the instructions or label provided by Defendants in practicing the claims of the 508 Patent, including at least claims 1, 2, 5, and 7, and wherein the Proposed ANDA Product is not a staple article or commodity of commerce suitable for substantial non-infringing use.

199. The 2025 Notice Letter purports to include a Notice of Certification for the ANDA under 37 C.F.R. § 314.95(c)(6) as to the 508 Patent. The 2025 Notice Letter did not include a detailed and supported statement of allegations of invalidity, unenforceability, or non-infringement for every claim of the 508 Patent.

200. On information and belief, Defendants have actual knowledge of the 508 Patent, at least as shown by the 2025 Notice Letter.

201. On information and belief, under 35 U.S.C. § 271(e)(2)(A), Defendants have infringed the claims of the 508 Patent, including at least claims 1, 2, 5, and 7, by submitting or causing to be submitted to the FDA, the ANDA seeking approval to manufacture, use, import, offer to sell or sell the Proposed ANDA Product before the expiration date of the 508 Patent.

202. On information and belief, the use of the Proposed ANDA Product, if approved and marketed, will infringe, either literally or under the doctrine of equivalents, at least one claim

of the 508 Patent, including at least claims 1, 2, 5, and 7, under at least one of 35 U.S.C. § 271(a), (b), or (c).

203. On information and belief, physicians and/or patients will directly infringe the claims of the 508 Patent, including at least claims 1, 2, 5, and 7, by the use of the Proposed ANDA Product upon approval.

204. On information and belief, upon approval, Defendants will take active steps to encourage the use of the Proposed ANDA Product by physicians and/or patients with the knowledge and intent that the Proposed ANDA Product will be used by physicians and/or patients, in a manner that infringes the claims of the 508 Patent, including at least claims 1, 2, 5, and 7, for the pecuniary benefit of Defendants.

205. On information and belief, Defendants specifically intend the Proposed ANDA Product to be used in a manner that infringes the claims of the 508 Patent, including at least claims 1, 2, 5, and 7. On information and belief, Defendants will actively induce the infringement of the claims of the 508 Patent, including at least claims 1, 2, 5, and 7.

206. On information and belief, Defendants' Proposed ANDA Product is specifically designed for use in a manner that infringes the claims of the 508 Patent, including at least claims 1, 2, 5, and 7. On information and belief, Defendants will thus contribute to the infringement of the claims of the 508 Patent, including at least claims 1, 2, 5, and 7.

207. On information and belief, the actions described in this Complaint relating to the ANDA and the 508 Patent were done by and for the benefit of Defendants.

208. Plaintiffs will be irreparably harmed by these infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

**COUNT X – CLAIM FOR INFRINGEMENT OF THE 952  
PATENT**

209. Plaintiffs re-allege each of the foregoing paragraphs as if fully set forth herein.

210. An actual controversy exists between the parties as to whether Defendants' proposed sale of the Proposed ANDA Product infringes the claims of the 952 Patent, including at least claims 6, 7, and 8.

211. On information and belief, the use of the Proposed ANDA Product will infringe at least claims 6, 7, and 8 of the 952 Patent because physicians and/or patients will practice a method of treating metastatic castration-sensitive prostate cancer in a male human, said method consisting essentially of administering a therapeutically effective amount of an anti-androgen to a male human with metastatic castration-sensitive prostate cancer, wherein the anti-androgen is apalutamide, wherein its dosage is decreased to 180 mg per day or 120 mg per day if the male human experiences a greater than or equal to Grade 3 toxicity.

212. On information and belief, Defendants will induce infringement of at least claims 6, 7, and 8 of the 952 Patent by actively inducing the use of the Proposed ANDA Product to practice a method of treating metastatic castration-sensitive prostate cancer in a male human, said method consisting essentially of administering a therapeutically effective amount of an anti-androgen to a male human with metastatic castration-sensitive prostate cancer, wherein the anti-androgen is apalutamide, wherein its dosage is decreased to 180 mg per day or 120 mg per day if the male human experiences a greater than or equal to Grade 3 toxicity.

213. On information and belief, if the FDA approves the ANDA, Defendants will sell or offer to sell the Proposed ANDA Product specifically labeled for use in practicing the claims of the 952 Patent, including at least claims 6, 7, and 8, wherein the Proposed ANDA Product is a material part of the claimed invention, wherein Defendants know that physicians will prescribe

and patients will use the Proposed ANDA Product in accordance with the instructions or label provided by Defendants in practicing the claims of the 952 Patent, including at least claims 6, 7, and 8, and wherein the Proposed ANDA Product is not a staple article or commodity of commerce suitable for substantial non-infringing use.

214. The 2025 Notice Letter purports to include a Notice of Certification for the ANDA under 37 C.F.R. § 314.95(c)(6) as to the 261 Patent. The 2025 Notice Letter did not include a detailed and supported statement of allegations of invalidity, unenforceability, or non-infringement for every claim of the 952 Patent.

215. On information and belief, Defendants have actual knowledge of the 952 Patent, at least as shown by the 2025 Notice Letter.

216. On information and belief, under 35 U.S.C. § 271(e)(2)(A), Defendants have infringed the claims of the 952 Patent, including at least claims 6, 7, and 8, by submitting or causing to be submitted to the FDA, the ANDA seeking approval to manufacture, use, import, offer to sell or sell the Proposed ANDA Product before the expiration date of the 952 Patent.

217. On information and belief, the use of the Proposed ANDA Product, if approved and marketed, will infringe, either literally or under the doctrine of equivalents, at least one claim of the 952 Patent, including at least claims 6, 7, and 8, under at least one of 35 U.S.C. § 271(a), (b), or (c).

218. On information and belief, physicians and/or patients will directly infringe the claims of the 952 Patent, including at least claims 6, 7, and 8, by their use of the Proposed ANDA Product upon approval.

219. On information and belief, upon approval, Defendants will take active steps to encourage the use of the Proposed ANDA Product by physicians and/or patients with the



knowledge and intent that the Proposed ANDA Product will be used by physicians and/or patients, in a manner that infringes the claims of the 952 Patent, including at least claims 6, 7, and 8, for the pecuniary benefit of Defendants.

220. On information and belief, Defendants specifically intend the Proposed ANDA Product to be used in a manner that infringes the claims of the 952 Patent, including at least claims 6, 7, and 8. On information and belief, Defendants will actively induce the infringement of the claims of the 952 Patent, including at least claims 6, 7, and 8.

221. On information and belief, Defendants' Proposed ANDA Product is specifically designed for use in a manner that infringes the claims of the 952 Patent, including at least claims 6, 7, and 8. On information and belief, Defendants will thus contribute to the infringement of the claims of the 952 Patent, including at least claims 6, 7, and 8.

222. On information and belief, the actions described in this Complaint relating to the ANDA and the 952 Patent were done by and for the benefit of Defendants.

223. Plaintiffs will be irreparably harmed by these infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

### **PRAYER FOR RELIEF**

**WHEREFORE**, Plaintiffs respectfully request that the Court enter judgment in their favor and against Defendants on the patent infringement claims set forth above and respectfully request that this Court:

A. Enter judgment under 35 U.S.C. § 271(e)(2)(A) that Defendants have infringed one or more claims of each of the Patents-In-Suit through the submission of the ANDA to the FDA to obtain approval to manufacture, use, import, offer to sell, and sell the Proposed ANDA Product in the United States before the expiration of the Patents-In-Suit;

B. Enter a declaratory judgment that pursuant to 35 U.S.C. § 271(a), (b), and/or (c), the commercial manufacture, use, offer for sale, or sale within the United States, or importation into the United States of the Proposed ANDA Product, prior to the expiration of the Patents-In-Suit, would constitute infringement of one or more claims of each of the Patents-In-Suit under 35 U.S.C. § 271 (a), (b), and/or (c);

C. Order that pursuant to 35 U.S.C. § 271(e)(4)(A) the effective date of any approval of the ANDA be a date that is not earlier than the expiration dates of the Patents-In-Suit, or such later date as the Court may determine;

D. Order that Defendants, their officers, agents, servants, and employees, and those persons in active concert or participation with Defendants, are preliminarily and permanently enjoined from commercially manufacturing, using, importing, offering for sale, and selling the Proposed ANDA Product, and any other product that infringes or induces or contributes to the infringement of the Patents-In-Suit, prior to the expiration of the Patents-In-Suit, or such later date as the Court may determine;

E. If Defendants engage in the commercial manufacture, use, offer for sale, sale, and/or importation into the United States of the Proposed ANDA Product prior to the expiration of the Patents-In-Suit, a judgment awarding damages to Plaintiffs resulting from such infringement together with interest;

F. Declare this to be an exceptional case under 35 U.S.C. §§ 285 and 271(e)(4) and award Plaintiffs their costs, expenses, and disbursements in this action, including reasonable attorney fees; and

G. Award such further and other relief as this Court deems proper and just.

Respectfully Submitted,

Dated: June 18, 2025

s/ Keith J. Miller  
Keith J. Miller, Esq.  
Michael J. Gesualdo, Esq.  
Bradley A. Suiters, Esq.  
**ROBINSON MILLER LLC**  
Ironsides Newark  
110 Edison Place, Suite 302  
Newark, New Jersey 07102  
Tel: (973) 690-5400  
Fax: (973) 466-2761  
Email: [kmiller@rwmlegal.com](mailto:kmiller@rwmlegal.com)  
[mgesualdo@rwmlegal.com](mailto:mgesualdo@rwmlegal.com)  
[bsuiters@rwmlegal.com](mailto:bsuiters@rwmlegal.com)

*Attorneys for Plaintiffs Aragon Pharmaceuticals,  
Inc., Janssen Biotech, Inc., The Regents of the  
University of California, and Sloan-Kettering  
Institute for Cancer Research*

*Of Counsel:*

Steven D. Maslowski  
Matthew A. Pearson  
Jonathan J. Underwood  
Anthony D. Sierra  
Vincent P. Jones  
Chih Yang Lin  
**AKIN GUMP STRAUSS HAUER & FELD  
LLP**  
1735 Market Street, 12<sup>th</sup> Floor  
Philadelphia, PA 19103  
Tel: (215) 965-1200  
Fax: (215) 965-1210  
[smaslowski@akingump.com](mailto:smaslowski@akingump.com)  
[mpearson@akingump.com](mailto:mpearson@akingump.com)  
[underwoodj@akingump.com](mailto:underwoodj@akingump.com)  
[asierra@akingump.com](mailto:asierra@akingump.com)  
[jonesv@akingump.com](mailto:jonesv@akingump.com)  
[mclin@akingump.com](mailto:mclin@akingump.com)

Golda Lai  
**AKIN GUMP STRAUSS HAUER & FELD  
LLP**

Robert S. Strauss Tower  
2001 K Street, N.W.  
Washington, D.C. 20006  
Tel: (202) 887-4000  
Fax: (202) 887-4288  
laig@akingump.com

Caitlin E. Olwell  
**AKIN GUMP STRAUSS HAUER & FELD  
LLP**

Bank of America Tower  
1 Bryant Park  
New York, NY 10036  
Tel: (212) 872-1000  
Fax: (202) 872-1002  
colwell@akingump.com

*Attorneys for Plaintiffs Aragon  
Pharmaceuticals, Inc., Janssen Biotech, Inc.,  
The Regents of the University of California,  
and Sloan-Kettering Institute for Cancer  
Research*

**CERTIFICATE PURSUANT TO RULES 11.2 AND 40.1**

I hereby certify that, to the best of my knowledge, the matter in controversy is not the subject of any other pending or anticipated litigation in any court or arbitration proceeding, except that Aragon and JBI have asserted one or more of the patents in this case (952 Patent) in the following pending matter in this Judicial District: *Aragon Pharms., Inc. et al v. Lupin Ltd. et al*, Civil Action No. 2:25-cv-02860-SRC-LDW. Further, there are not any non-parties known to Plaintiffs that should be joined to this action. In addition, I recognize a continuing obligation during the course of this litigation to file and to serve on all other parties and with the Court an amended certification if there is a change in the facts stated in this original certification.

Dated: June 18, 2025

Respectfully Submitted,

s/ Keith J. Miller

Keith J. Miller, Esq.

Michael J. Gesualdo, Esq.

Bradley A. Suiters, Esq.

**ROBINSON MILLER LLC**

Ironside Newark

110 Edison Place, Suite 302

Newark, New Jersey 07102

Tel: (973) 690-5400

Fax: (973) 466-2761

Email: [kmiller@rwmlegal.com](mailto:kmiller@rwmlegal.com)

[mguesualdo@rwmlegal.com](mailto:mguesualdo@rwmlegal.com)

[bsuiters@rwmlegal.com](mailto:bsuiters@rwmlegal.com)

*Attorneys for Plaintiffs Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., The Regents of the University of California, and Sloan-Kettering Institute for Cancer Research*